Background: Glucagon-like peptide-1 (GLP-1) agonists are increasingly prescribed for obesity and type 2 diabetes, demonstrating efficacy in weight loss and glycemic control [1-3]. Beyond metabolic effects, these medications show protective effects against renal disease progression and reduce major adverse cardiovascular events [4]. GLP-1 agonists influence body composition through effects on both fat mass and fat-free [...]

Background: Glucagon-like peptide-1 (GLP-1) agonists are increasingly prescribed for obesity and type 2 diabetes, demonstrating efficacy in weight loss and glycemic control [1-3]. Beyond metabolic effects, these medications show protective effects against renal disease progression and reduce major adverse cardiovascular events [4]. GLP-1 agonists influence body composition through effects on both fat mass and fat-free [...]

Case Presentation: A 62-year-old female presented to the Emergency Department with 48 hours of persistent palpitations and a week of poor oral intake, polydipsia, and polyuria. Her past medical history included Type II Diabetes Mellitus treated long-term with metformin and dapagliflozin. Two weeks before presenting to the Emergency Department, she transitioned from dulaglutide to tirzepatide [...]